Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Eukaryotic Gene Expression
Factor de Impacto: 1.841 Factor de Impacto de 5 años: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN Imprimir: 1045-4403
ISSN En Línea: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2013006917
pages 103-113

Combined Gene Expression and DNA Occupancy Profiling as a Strategy to Identify Therapeutic Target(s) in t(8;21) Acute Myeloid Leukemia

Miao-Chia Lo
Moores Cancer Center, University of California San Diego, La Jolla, California
Luke F. Peterson
Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan

SINOPSIS

Microarray technology has contributed valuable information to gene expression signatures of leukemia and other types of cancers and helped to identify biological markers and potential therapeutic targets for treating these diseases. Acute myeloid leukemia (AML) is often caused by aberrant fusion transcription factors resulting from chromosomal translocations, and the dysregulated genes detected by microarray include both direct and indirect targets of the oncogenic transcription factors. The ChIP-chip technology enables the identification of direct targets of a transcription factor based on its promoter occupancy and cellular context. Using AML1-ETO9a-induced AML as a cancer model and using a combined gene expression and promoter occupancy profiling approach, we recently identified CD45 as a direct down-regulated target of t(8;21) fusion proteins. This finding subsequently led us to discover the enhanced Janus activated kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway, which is negatively regulated by CD45, in t(8;21) AML. This review summarizes the background of t(8;21) leukemia, structural features of the translocation fusion proteins, and the merits of combining gene discovery technologies for the identification of therapeutic targets in t(8;21) leukemia.


Articles with similar content:

Therapeutic Targeting of BCR-ABL: Prognostic Markers of Response and Resistance Mechanism in Chronic Myeloid Leukaemia
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 1
Timothy P. Hughes, David T. Yeung
Indirect and Direct Disruption of Transcriptional Regulation in Cancer: E2F and AML-1
Critical Reviews™ in Eukaryotic Gene Expression, Vol.5, 1995, issue 3-4
Shari Meyers , Scott W. Hiebert
Roles of Smad3 in TGF-β Signaling During Carcinogenesis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.17, 2007, issue 4
Caroline Millet, Ying E. Zhang
AML1-ETO—Mediated Erythroid Inhibition: New Paradigms for Differentiation Blockade by a Leukemic Fusion Protein
Critical Reviews™ in Eukaryotic Gene Expression, Vol.15, 2005, issue 3
Kamaleldin E. Elagib, Adam N. Goldfarb, Youngjin Choi
The Transcription Regulator Kruppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
Swapan K. Ray